| Category | Details |
| Definition | Epilepsy is a chronic neurological disorder characterized by recurrent seizures caused by abnormal brain electrical activity. |
| Global Epidemiology | – Over 50 million people worldwide are affected by epilepsy. |
| – Around 70% of cases are treatable with proper management. |
| – Low- and middle-income countries bear 80% of the global epilepsy burden. |
| Prevalence in Key Regions | – United States: 3.4 million with active epilepsy (~1.2% of the population). |
| – European Union: 6 million cases, ~400,000 new annually. |
| – India: ~12 million, representing one-sixth of global epilepsy cases. |
| – China: Over 9 million individuals affected. |
| – Sub-Saharan Africa: 10–20 cases per 1,000 individuals. |
| – Caribbean: Estimated 500,000 people with epilepsy. |
| Medicinal Cannabis Approvals | – United States (FDA): Epidiolex (CBD solution) approved in 2018 for Lennox-Gastaut and Dravet syndromes. |
| – European Union (EMA): Epidyolex approved in 2019 for adjunctive therapy in Lennox-Gastaut and Dravet syndromes. |
| – Brazil (ANVISA): CBD authorized for epilepsy case-by-case since 2015. |
| – Australia (TGA): Epidiolex approved in 2019 for severe epilepsy syndromes. |
| – Israel: Medical cannabis approved for treatment-resistant epilepsy since 2013. |
| – South Africa: CBD-based therapies approved for refractory epilepsy in 2019. |
| Therapeutic Cannabinoids | – CBD (Cannabidiol): Well-documented anticonvulsant effects, interacts with GPR55, TRPV1, and 5-HT1A receptors. |
| – THCV (Tetrahydrocannabivarin): Emerging evidence supports anticonvulsant properties via partial agonism at CB1 receptors and modulation of TRPV channels. |
| – CBG (Cannabigerol): Potential neuroprotective effects and anti-inflammatory properties; under investigation for reducing seizure severity. |
| – CBN (Cannabinol): Mild anticonvulsant properties; limited evidence compared to CBD and THC but may enhance sedative effects in combination. |
| – Delta-8-THC: Less psychoactive than Delta-9-THC, early studies suggest mild anticonvulsant activity. |
| Mechanism of Action | – CBD: Reduces hyperexcitability in neuronal pathways by modulating GPR55 and TRPV1 receptors. |
| – Decreases neuroinflammation via CB2 receptor pathways, potentially enhancing seizure control. |
| – THCV: Acts as a partial CB1 antagonist at low doses and a weak agonist at higher doses, potentially reducing excitotoxicity in epileptic seizures. |
| Key Clinical Studies | – Devinsky et al., 2017: Epidiolex trial showed a 44% reduction in seizures for Lennox-Gastaut patients. |
| – Porter & Jacobson, 2013: Parent survey showed 84% improvement in seizure control with CBD-enriched oils. |
| – Pamplona et al., 2018: Suggested synergistic effects of minor cannabinoids and terpenes in seizure reduction (“Entourage Effect”). |
| Clinical Effectiveness | – Dravet Syndrome: 50% seizure reduction in 39% of patients using Epidiolex. |
| – Lennox-Gastaut Syndrome: Median seizure reduction of 44% across clinical trials. |
| Dosage Guidelines | – Oral (Epidiolex CBD): Start at 2.5 mg/kg twice daily, increase to 10 mg/kg twice daily as maintenance (up to 20 mg/kg/day). |
| – Sublingual Oils (CBD): Typical ranges are 5–50 mg/day depending on patient response; individualized dosing required. |
| – Vaporized THC/CBD: 2.5–10 mg per session; not widely recommended for epilepsy due to dosing variability. |
| – THCV (Experimental): Preclinical doses of 5–10 mg/day have shown anticonvulsant effects. |
| – CBG/CBN: Dosing not established; experimental ranges of 2–10 mg/kg/day used in early studies. |
| Administration Methods | – Oral Solutions: Epidiolex ensures consistent dosing with bioavailability ~6–15%. |
| – Sublingual Oils: Provides rapid absorption but requires careful dosing precision. |
| – Inhalation (Vaporized THC/CBD): Rarely used for epilepsy; dosing variability and psychoactive risks limit its use. |
| Adverse Effects | – CBD: Common: Somnolence, appetite loss, diarrhea. Rare: Elevated liver enzymes in ~15% of patients. |
| – THC: Risks include dizziness, anxiety, and potential dependence; not recommended for pediatric use. |
| – CBN: Sedation at higher doses; limited long-term safety data. |
| Research Gaps | – Long-term safety and efficacy of minor cannabinoids like THCV and CBG remain under-researched. |
| – Cannabinoid interactions with standard antiepileptic drugs require further pharmacokinetic studies. |
| Opportunities in the Caribbean | – High prevalence of untreated epilepsy (~30–40%). |
| – Specialized cannabis clinics could address local health needs and attract medical tourists seeking advanced therapies. |
| – Research collaborations with global institutions could establish the region as a leader in epilepsy innovation. |
